AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Major deals, including Johnson & Johnson’s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly ...

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, is navigating a critical phase in its development pipeline. With several key ...

Gilead Sciences' cell therapy Kite Pharma has ... Xanthopoulos said the deal will "potentially accelerate Shoreline's timeline to the clinic, expand our pipeline opportunities and deliver ...

The company's potential partnership with Gilead Sciences (NASDAQ ... the company to reevaluate its development strategy and timeline. What risks does the company face in terms of financial ...

A spokesperson for Advanz told pharmaphorum that, at the moment, the company does not have a timeline for when a ... Another potential option is Gilead Sciences PPAR agonist Livdelzi (seladelpar ...

Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...

Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.